The acute phase reactant response to respiratory infection with Chlamydia pneumoniae: Implications for the pathogenesis of atherosclerosis

Microbes and Infection

Volumn 12, Issue 8-9, 2010, Pages 598-606

  Campbell, Lee Ann ^a   Yaraei, Kambiz ^a   Van Lenten, Brian ^b   Chait, Alan ^c   Blessing, Erwin ^a   Kuo, Cho Chou ^a   Nosaka, Tadayoshi ^a   Ricks, Jerry ^c   Rosenfeld, Michael E ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Chlamydia pneumoniae; Cytokines; Inflammation; Mice

Indexed keywords

APOLIPOPROTEIN E; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; ACUTE PHASE PROTEIN;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHLAMYDIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; DISEASE COURSE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ANIMAL; BACTERIAL PNEUMONIA; BLEEDING; C57BL MOUSE; CHEMICALLY INDUCED; CHLAMYDOPHILA INFECTION; COMPLICATION; IMMUNOLOGY; PATHOGENICITY; PATHOLOGY; SECRETION (PROCESS);

ACUTE-PHASE PROTEINS; ANIMALS; ATHEROSCLEROSIS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HEMORRHAGE; MALE; MICE; MICE, INBRED C57BL; PNEUMONIA, BACTERIAL;

CHLAMYDOPHILA PNEUMONIAE; MUS;

EID: 77954953757     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2010.04.001     Document Type: Article

References (50)

1. Kuo C.-C., Jackson L.A., Campbell L.A., Grayston J.T. Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev. 1995, 8:451-461.
2. Kuo C.-C., Campbell L.A. Chlamydia pneumoniae - an infectious risk factor for atherosclerosis?. Nat. Rev. Microbiol. 2004, 2:23-32.
3. Jousilahti P., Salomaa V., Rasi V., Vahtera E., Paloso T. The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease. Baseline findings of the PAIS project. Atherosclerosis 2001, 156:451-456.
4. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 23/2000, 342:836-843.
5. Lewis K.E., Kirk E.A., McDonald T.O., Wang S., Wight T.N., O'Brien K.D., Chait A. Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation 2004, 110:540-545.
6. Kol A., Sokova G.K., Lichtman A.H., Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998, 98:300-307.
7. Johnston S.C., Zhang H., Messing L.M., Lawton M.T., Dean D. Chlamydia pneumoniae burden in carotid arteries is associated with upregulation of plaque interleuikin-6 and elevated C-reactive protein in serum. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2648-2653.
8. Redecke V., Dalhoff K., Bohnet S., Braun J., Maass M. Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response. Am. J. Respir. Cell Mol. Biol. 1998, 19:721-727.
9. Presta M., Camozzi M., Salvatori G., Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J. Cell. Mol. Med. 2007, 11:723-728.
10. Lenten B.V., Wagner A.C., Nayak D.P., Hama S., Navab M., Fogelman A.M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza infection. Circulation 2001, 103:2283-2288.
11. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of high-density lipoprotein associated PON. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 1995, 96:2882-2991.
12. Kol A., Bourcier T., Lichtman A.H., Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J. Clin. Invest. 1999, 103:571-577.
13. Kaukoranta-Tolvanen S.S., Teppo A.M., Laitinen K., Saikku P., Linnavuori K., Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb. Pathog. 1996, 21:215-221.
14. Hogdahl M., Soderulund G., Kihlstrom E. Expression of chemokines and adhesion molecules in human coronary artery endothelial cells infected with Chlamydia (Chlamydophila) pneumoniae. APMIS 2008, 116:1082-1088.
15. Rosenfeld M.E., Polinsky P., Virmani R., Kauser K., Rubanyi G., Schwartz S.M. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2587-2592.
16. Schwartz S.M., Galis Z.S., Rosenfeld M.E., Falk E. Plaque rupture in humans and mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:705-713.
17. Kuo C.-C., Grayston J.T. A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumoniae strain TWAR. J. Infect. Dis. 1990, 162:75-78.
18. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase, evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 1991, 19:100-106.
19. Navab M., Hama S.Y., Hough G.P., Subbanagounder G., Reddy S.T., Fogelman A.M. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 2001, 42:1308-1316.
20. Elbadawi A. Hexachrome modification of Movat's stain. Stain Technol. 1976, 51:249-253.
21. Bills C.E., Eisenberg H., Pallante S.L. Complexes of organic acids with calcium phosphate: the Von Kossa stain as a clue to the composition of bone mineral. Johns Hopkins Med. J. 1974, 128:194-207.
22. Rattazzi M., Bennett B.J., Bea F., Kirk E.A., Ricks J.L., Speer M., Schwartz S.M., Giachelli C.M., Rosenfeld M.E. Calcification of advanced atherosclerotic lesions in the innominate arteries of ApoE-deficient mice: potential role of chondrocyte-like cells. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1420-1425.
23. Caspar-Bauguil S., Puissant B., Nazzal D., Lefevre J.-C., Thomsen M., Salvayre R., Benoist H. Chlamydia pneumoniae induces interleukin-10 production that down-regulates major histocompatibility complex class I expression. J. Infect. Dis. 2000, 182:1394-1401.
24. Rödel J., Woytas M., Groh A., Schmidt K.H., Hartmann M., Lehmann M., Straube E. Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect. Immun. 2000, 68:3635-3641.
25. Yang J., Hooper W.C., Phillips D.J., Tondella M.L., Talkington D.F. Induction of proinflammatory cytokines in human lung epithelial cells during Chlamydia pneumoniae infection. Infect. Immun. 2003, 71:614-620.
26. Kragsbjerg P., Vikerfors T., Holmberg H. Cytokine responses in patients with pneumonia caused by Chlamydia or Mycoplasma. Respiration 1998, 65:299-303.
27. Blasi F., Aliberti S., Allegra L., Piatti G., Tarsia P., Osserwaarde J.M., Verwej V., Nijkamp F.P., Folkerts G. Chlamydophila pneumoniae induces a sustained airway hyperresponsiveness and inflammation in mice. Respir. Res. 2007, 8:83.
28. Mueller M., Postius S., Thimm J.G., Gueinzius K., Muehldorfer I., Hermann C. Toll-like receptors 2 and 4 do not contribute to clearance of Chlamydophila pneumoniae in mice, but are necessary for the release of monokines. Immunobiology 2004, 209:599-608.
29. Milburn M.V., Hassell A.M., Lambert M.H., Jordan S.R., Proudfoot A.E., Graber P., Wells T.N. A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature 1993, 363:172-176.
30. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. J. Biochem. 1990, 265:621-636.
31. Fleming S.D., Campbell P.A. Macrophages have cell surface IL-10 that regulates macrophage bactericidal activity. J. Immunol. 1996, 156:1143-1150.
32. Geng Y., Berencsi K., Gyulai Z., Valyi-Nagy T., Gonczol E., Trinchieri G. Roles of interleukin-12 and gamma interferon in murine Chlamydia pneumoniae infection. Infect. Immun. 2000, 68:2245-2253.
33. Goldman M., Velu T., Petrolani M. Interleukin-10. Actions and therapeutic potentials. Biodrugs 1997, 7:6-14.
34. Bolinger A.M., Taeubel M.A. Recombinant interferon gamma for treatment of chronic granulomatous diseases and other disorders. Clin. Pharm. 1992, 11:834-850.
35. Beatty W.L., Belanger T.A., Desai A.A., Morrison R.P., Byrne G.I. Tryptophan depletion as a mechanism of γinterferon-mediated chlamydial persistence. Infect. Immun. 1994, 62:3705-3711.
36. Thomas S., Garrity L., Brandt C., Shobert S., Feng G., Taylor M., Carlin J., Byrne G. IFN-γ-mediated antimicrobial response: indoleamine 2,3 dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth. J. Immunol. 1993, 150:5529-5534.
37. Igietseme J.U., Uriri I.M., Chow M., Abe E., Rank R.G. Inhibition of intracellular multiplication of human strains of Chlamydia trachomatis by nitric oxide. Biochem. Biophys. Res. Commun. 1997, 232:595-601.
38. Mehta S.J., Miller R.D., Ramirez J.A., Summersgill J.T. Inhibition of Chlamydia pneumoniae replication in hep-2 cells by interferon-γ: role of tryptophan catabolism. J. Infect. Dis. 1998, 177:1326-1331.
39. Frostergard J., Ulfgren A.-K., Nyberg P., Hedin U., Sweendborg J., Andersson U., Hansson G.K. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory Th1 and macrophage stimulating cytokines. Atherosclerosis 1999, 145:33-43.
40. Han C.Y., Chiba T., Campbell J.S., Fausto N., Chaisson M., Orasanu G., Plutzky J., Chait A. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1806-1813.
41. Ezzahiri R., Stassen F.R., Kurvers H.R., Dolmans V., Kitslaar P.J., Bruggeman C.A. Chlamydia pneumoniae infections augment atherosclerotic lesion formation: a role for serum amyloid P. Apmis 2006, 114:117-126.
42. Moazed T.C., Campbell L.A., Rosenfeld M.E., Grayston J.T., Kuo C.C. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J. Infect. Dis. 1999, 180:238-241.
43. Blessing E., Campbell L.A., Rosenfeld M.E., Chough N., Kuo C.C. Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis 2001, 158:13-17.
44. Hu H., Pierce G.N., Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J. Clin. Invest. 1999, 103:747-753.
45. Ezzahiri R., Stassen F.R., Kurvers H.A., van Pul M.M., Kitslaar P.J., Bruggeman C.A. Chlamydia pneumoniae infection induces an unstable atherosclerotic plaque phenotype in LDL-receptor, ApoE double knockout mice. Eur. J. Vasc. Endovasc. Surg. 2003, 26:88-95.
46. Depre C., Havaux X., Wijns W. Neovascularization in human coronary atherosclerotic lesions. Cathet. Cardiovasc. Diagn. 1996, 39:215-220.
47. Moulton K.S., Heller E., Konerding M.A., Flynn E., Palinski W., Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999, 99:1726-1732.
48. Virok D., Loboda A., Kari L., Nebozhyn M., Chang C., Nichols C., Endresz V., Gonczol E., Berencsi K., Showe M.K., Showe L.C. Infection of U937 monocytic cells with Chlamydia pneumoniae induces extensive changes in host cell gene expression. J. Infect. Dis. 2003, 188:1310-1321.
49. Kahler J., Gerth S., Schafer P., Boersma E., Koster R., Terres W., Simoons M.L., Berger J., Meinertz T., Hamm C.W. Antibodies to chlamydial lipopolysaccharides in unstable angina pectoris. Am. J. Cardiol. 2001, 87:1150-1153.
50. Higuchi M., Castelli J.B., Aiello V.D., Palomino S., Reis M.M., Sambiase N.V., Fukasawa S., Bezerra H.G., Ramires J.A. Great amount of C. pneumoniae in ruptured plaque vessel segments at autopsy. A comparative study with stable plaques. Arq. Bras. Cardiol. 2000, 74:149-151.